Bezlotoxumab
Bezlotoxumab Uses, Dosage, Side Effects, Food Interaction and all others data.
Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Used to reduce the recurrence of Clostridium difficle infection in adults receiving antibiotic therapy to treat C. difficile infection and high risk of recurrence.
Bezlotoxumab binds to C.difficile toxin B, a virulence factor common to practically all C.difficile, which prevents the bacteria from infecting host cells. Bezlotoxumab binds two epitopes of toxin B, via two Fab regions, which partially blocks the carbohydrate binding pockets of the toxin resulting in the prevention of toxin B from binding to host cells.
Trade Name | Bezlotoxumab |
Availability | Prescription only |
Generic | Bezlotoxumab |
Bezlotoxumab Other Names | Bezlotoxumab |
Related Drugs | Zinplava |
Weight | 25mg/ml, |
Type | Intravenous Solution, Intravenous |
Protein binding | Binds to C.difficile virulence factor toxin B which prevents its action on host cells. |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Bezlotoxumab is a monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
Prevents recurrence of Clostridium difficile infection in people 18 years or older who are either currently receiving treatment for C. difficile infection or have a high risk of recurrence.
Bezlotoxumab is also used to associated treatment for these conditions: Clostridium difficile infection recurrence
How Bezlotoxumab works
A single molecule of bezlotoxumab neutralizes Toxin B by binding its two Fab regions to two epitopes within the N-terminal half of the Toxin B CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells.
Toxicity
No data available on overdosage.
Food Interaction
No interactions found.Bezlotoxumab Disease Interaction
Volume of Distribution
7.33L
Elimination Route
Not absorbed since give IV
Half Life
19 Days
Clearance
0.317 L/day
Elimination Route
Catabolism
Innovators Monograph
You find simplified version here Bezlotoxumab